News
FDA starts speedy review of Imfinzi in bladder cancer
AstraZeneca is closing on FDA approval of a new bladder cancer indication for Imfinzi that could help to fend off encroachment from MSD's Keytruda.
Oncology
Australia, CAR-T therapy, and solid tumours
Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.
News
Grail cancer test gets lukewarm backing from FDA adcomm
FDA expert advisors voted in favour of Grail's Galleri blood test for detecting multiple cancers, but some expressed misgivings about its efficacy.
Oncology
Getting predictive technologies to patients, with Concr
Dr Irina Babina, CEO of oncology R&D platform Concr, discusses how current regulatory frameworks were built for static diagnostics.
News
Telix to buy radiopharma rival ITM for $1.65bn upfront
Telix Pharma has reached a deal to acquire ITM, extending a wave of consolidation in the radiopharma category over the last couple of years.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
